{"SPADE_UN_11342": {"Clinical Information": [{"Medical use": "Treatment for chemotherapeutic induced neutropenia, nosocomial infections", "Company": "Inimex", "Stage of Development": "Phase II", "Comments": "Phase Ia trial completed in 2009", "Clinical Trials": [31438824]}, {"Medical use": "Prevention of infections in the immune compromised", "Company": "Unknown", "Stage of Development": "Phase I", "Comments": "Immunomodulation, protection of }monocytes", "Clinical Trials": []}], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_11342", "Peptide Name": "IMX942(Inimex)", "Sequence": "KSRIVPAIPVSLL", "Source": "Synthetic cationic host defense peptide,derivative of IDR-1 and indolicidin", "Target Organism": "No MICs found on DRAMP database", "Reference": ["Potential of immunomodulatory host defense peptides as novel anti-infectives.Trends in Biotechnology(2009).(PMID:19683819)"], "Biological Activity": ["Broad spectrum"], "Frequent Amino Acids": "ILP", "Absent Amino Acids": "CDEFGHMNOQTUWY", "Basic Residues": 2, "Acidic Residues": 0, "Hydrophobic Residues": 9, "Polar Residues": 7, "Positive Residues": 2, "Negative Residues": 0, "Mass": 1392.73, "PI": 11.0, "Net Charge": 2, "Hydrophobicity": 1.05, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_11589", "Similarity": 1.0, "Sequence": "RIVPA"}, {"SPADE_ID": "SPADE_UN_26539", "Similarity": 0.7142857142857143, "Sequence": "FIPVSGLFKLL"}, {"SPADE_ID": "SPADE_UN_08018", "Similarity": 0.6666666666666666, "Sequence": "MKAIPVALLLLVLVAAASSFKHLAEAADGGAVPDGVCDGKCRSRCSLKKAGRCMGLCMMCCGKCQGCVPSGPYASKDECPCYRDMKSPKNQRPKCP"}]}}}